ESGAR consensus statement on liver MR imaging and clinical use of liver-specific contrast agents
暂无分享,去创建一个
Jeong Min Lee | E. Merkle | E. Neri | C. Bartolozzi | V. Vilgrain | C. Matos | A. Ba-Ssalamah | W. Schima | T. Helmberger | L. Martí-Bonmatí | R. Manfredi | C. Zech | P. Boraschi | G. Brancatelli | L. Grazioli | F. Alves | M. Bali | S. Skehan | B. O. Beeck | J. Lee | B. Op de Beeck | Riccardo Manfredi | Ba-Ssalamah Ahmed
[1] M. Ronot,et al. Hepatocellular carcinoma: diagnostic criteria by imaging techniques. , 2014, Best practice & research. Clinical gastroenterology.
[2] F. Donati,et al. Postoperative biliary adverse events following orthotopic liver transplantation: assessment with magnetic resonance cholangiography. , 2014, World journal of gastroenterology.
[3] Jin-Young Choi,et al. CT and MR imaging diagnosis and staging of hepatocellular carcinoma: part I. Development, growth, and spread: key pathologic and imaging aspects. , 2014, Radiology.
[4] A. Schreyer,et al. MRI-based estimation of liver function: Gd-EOB-DTPA-enhanced T1 relaxometry of 3T vs. the MELD score , 2014, Scientific Reports.
[5] D. Mitchell,et al. Gadolinium contrast agent selection and optimal use for body MR imaging. , 2014, Radiologic clinics of North America.
[6] M. Ohliger,et al. MR imaging of diffuse liver disease: from technique to diagnosis. , 2014, Radiologic clinics of North America.
[7] F. Miller,et al. MR imaging of benign focal liver lesions. , 2014, Radiologic clinics of North America.
[8] A. Schreyer,et al. Assessing liver function by liver enhancement during the hepatobiliary phase with Gd-EOB-DTPA-enhanced MRI at 3 Tesla , 2014, European Radiology.
[9] B. Choi,et al. Small (≤1-cm) hepatocellular carcinoma: diagnostic performance and imaging features at gadoxetic acid-enhanced MR imaging. , 2014, Radiology.
[10] Min Ju Kim,et al. Chemotherapy-induced focal hepatopathy in patients with gastrointestinal malignancy: gadoxetic acid--enhanced and diffusion-weighted MR imaging with clinical-pathologic correlation. , 2014, Radiology.
[11] A. Ba-Ssalamah,et al. P4 radiology of hepatobiliary diseases with gadoxetic acid-enhanced MRI as a biomarker , 2014, Expert review of gastroenterology & hepatology.
[12] S. Phongkitkarun,et al. Added value of hepatobiliary phase gadoxetic acid-enhanced MRI for diagnosing hepatocellular carcinoma in high-risk patients. , 2013, World journal of gastroenterology.
[13] Young Kon Kim,et al. The MR imaging diagnosis of liver diseases using gadoxetic acid: Emphasis on hepatobiliary phase , 2013, Clinical and molecular hepatology.
[14] Michael Haimerl,et al. Added value of Gd-EOB-DTPA-enhanced Hepatobiliary phase MR imaging in evaluation of focal solid hepatic lesions , 2013, BMC Medical Imaging.
[15] P. Wiggermann,et al. Impact of liver cirrhosis on liver enhancement at Gd-EOB-DTPA enhanced MRI at 3 Tesla. , 2013, European journal of radiology.
[16] F. Donati,et al. Biliary-enteric anastomoses: spectrum of findings on Gd-EOB-DTPA-enhanced MR cholangiography , 2013, Abdominal Imaging.
[17] P. Chow,et al. Consensus report of the Fifth International Forum for Liver MRI. , 2013, AJR. American journal of roentgenology.
[18] R. Semelka,et al. Enhancement of the liver and pancreas in the hepatic arterial dominant phase: Comparison of hepatocyte‐specific MRI contrast agents, gadoxetic acid and gadobenate dimeglumine, on 3 and 1.5 tesla MRI in the same patient , 2013, Journal of magnetic resonance imaging : JMRI.
[19] A. Ba-Ssalamah,et al. Preoperative evaluation of colorectal liver metastases: comparison between gadoxetic acid-enhanced 3.0-T MRI and contrast-enhanced MDCT with histopathological correlation , 2013, European Radiology.
[20] M. Reiser,et al. Imaging features of intrahepatic cholangiocarcinoma in Gd-EOB-DTPA-enhanced MRI. , 2013, European journal of radiology.
[21] L. Bolondi,et al. Impact of gadoxetic acid (Gd‐EOB‐DTPA)‐enhanced magnetic resonance on the non‐invasive diagnosis of small hepatocellular carcinoma: a prospective study , 2013, Alimentary pharmacology & therapeutics.
[22] Young Kon Kim,et al. Small intrahepatic mass-forming cholangiocarcinoma: target sign on diffusion-weighted imaging for differentiation from hepatocellular carcinoma , 2013, Abdominal Imaging.
[23] Carlo Bartolozzi,et al. Contrast-enhanced magnetic resonance imaging of 102 nodules in cirrhosis: correlation with histological findings on explanted livers , 2013, Abdominal Imaging.
[24] E. Merkle,et al. Diagnosis of focal nodular hyperplasia with MRI: multicenter retrospective study comparing gadobenate dimeglumine to gadoxetate disodium. , 2012, AJR. American journal of roentgenology.
[25] H. Hussain,et al. Primovist, Eovist: what to expect? , 2012, Journal of hepatology.
[26] H. C. Yu,et al. Diagnostic efficacy of gadoxetic acid-enhanced MRI for the detection and characterisation of liver metastases: comparison with multidetector-row CT. , 2012, The British journal of radiology.
[27] U. Motosugi,et al. Hepatocellular adenoma and focal nodular hyperplasia: value of gadoxetic acid-enhanced MR imaging in differential diagnosis. , 2012, Radiology.
[28] Myeong-Jin Kim,et al. Accuracy of gadoxetic acid-enhanced magnetic resonance imaging for the diagnosis of sinusoidal obstruction syndrome in patients with chemotherapy-treated colorectal liver metastases , 2012, European Radiology.
[29] M. Kudo. Diagnostic Imaging of Hepatocellular Carcinoma: Recent Progress , 2011, Oncology.
[30] C. Sirlin,et al. Diagnostic challenges and pitfalls in MR imaging with hepatocyte-specific contrast agents. , 2011, Radiographics : a review publication of the Radiological Society of North America, Inc.
[31] Y. Ohno,et al. A case of Budd-Chiari syndrome: Gd-EOB-DTPA-enhanced MR findings. , 2011, Magnetic resonance imaging.
[32] G. Guyatt,et al. GRADE guidelines: 1. Introduction-GRADE evidence profiles and summary of findings tables. , 2011, Journal of clinical epidemiology.
[33] N. Faccioli,et al. Solid Hypervascular Liver Lesions: Accurate Identification of True Benign Lesions on Enhanced Dynamic and Hepatobiliary Phase Magnetic Resonance Imaging After Gadobenate Dimeglumine Administration , 2011, Investigative radiology.
[34] C. Zuiani,et al. Comparison of Portal Venous and Delayed Phases of Gadolinium-Enhanced Magnetic Resonance Imaging Study of Cirrhotic Liver for the Detection of Contrast Washout of Hypervascular Hepatocellular Carcinoma , 2010, Journal of computer assisted tomography.
[35] S. Shankar,et al. Focal nodular hyperplasia: Central scar enhancement pattern using gadoxetate disodium , 2010, Journal of magnetic resonance imaging : JMRI.
[36] Elmar M Merkle,et al. Gadoxetate disodium-enhanced MRI of the liver: part 1, protocol optimization and lesion appearance in the noncirrhotic liver. , 2010, AJR. American journal of roentgenology.
[37] D. Choi,et al. Gadoxetic Acid (Gd-EOB-DTPA)-Enhanced MRI versus Gadobenate Dimeglumine (Gd-BOPTA)-Enhanced MRI for Preoperatively Detecting Hepatocellular Carcinoma: an Initial Experience , 2010, Korean journal of radiology.
[38] G. Kim,et al. Biliary MR imaging with Gd-EOB-DTPA and its clinical applications. , 2009, Radiographics : a review publication of the Radiological Society of North America, Inc.
[39] Sukru Mehmet Erturk,et al. Use of 3.0-T MR imaging for evaluation of the abdomen. , 2009, Radiographics : a review publication of the Radiological Society of North America, Inc.
[40] Onofrio A Catalano,et al. Hepatobiliary-specific MR contrast agents: role in imaging the liver and biliary tree. , 2009, Radiographics : a review publication of the Radiological Society of North America, Inc.
[41] R. Semelka,et al. Liver MR imaging: 1.5T versus 3T. , 2007, Magnetic resonance imaging clinics of North America.
[42] C. Kuhl,et al. High-field-strength MR imaging of the liver at 3.0 T: intraindividual comparative study with MR imaging at 1.5 T. , 2006, Radiology.
[43] Jae Young Lee,et al. Superparamagnetic Iron Oxide-Enhanced Liver Magnetic Resonance Imaging: Comparison of 1.5 T and 3.0 T Imaging for Detection of Focal Malignant Liver Lesions , 2006, Investigative radiology.
[44] E. Merkle,et al. Abdominal MR imaging at 3T. , 2006, Magnetic resonance imaging clinics of North America.
[45] R. Semelka,et al. Contrast agents for MR imaging of the liver. , 2005, Radiologic clinics of North America.
[46] G. Morana,et al. Accurate differentiation of focal nodular hyperplasia from hepatic adenoma at gadobenate dimeglumine-enhanced MR imaging: prospective study. , 2005, Radiology.
[47] Glenn Regehr,et al. Delphi as a method to establish consensus for diagnostic criteria. , 2003, Journal of clinical epidemiology.
[48] M. Bellin,et al. Currently used non-specific extracellular MR contrast media , 2003, European Radiology.
[49] P. Meier,et al. Hepatic uptake of the magnetic resonance imaging contrast agent gadoxetate by the organic anion transporting polypeptide Oatp1. , 1999, The Journal of pharmacology and experimental therapeutics.
[50] G Bravo,et al. Estimating the reliability of continuous measures with Cronbach's alpha or the intraclass correlation coefficient: toward the integration of two traditions. , 1991, Journal of clinical epidemiology.
[51] L. Cronbach. Coefficient alpha and the internal structure of tests , 1951 .
[52] F. Mosteller. Remarks on the method of paired comparisons: I. The least squares solution assuming equal standard deviations and equal correlations , 1951 .